- About Us
- Services & Solutions
- Technologies
- Discovery
- Reagent Materials Generation
- Monoclonal Antibody Discovery
- Bispecific & Multispecific Antibody Generation
- Lead Optimization
- In Vitro Lead Characterization
- In Vivo Lead Characterization
- Other Molecular Modalities
- IND Filing Support
- Protein Sciences
- Antibody Production
- Protein Production
- Protein Characterization
- Protein Sciences
- Mammalian
- Microbial
- mRNA
- Viral Vaccines
- WuXi XDC – Bioconjugation
- Testing
- Sustainability
- Careers
- Investors
- News & Resources
WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- SustainabilityAbout Us
- CareersAbout Us
- InvestorsAbout Us
- News & ResourcesAbout Us
Press Releases
2018
WuXi Biologics Congratulates Aravive Biologics on Achieving Proof-of-Mechanism for Novel Biologic AVB-S6-500 within 20 Months from Cell Line Development
WuXi Biologics Congratulates Aravive Biologics on Achieving Proof-of-Mechanism for Novel Biologic AVB-S6-500 within 20 Months from Cell Line Development
SHANGHAI, May 14, 2018 — WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, congratulates its partner Aravive Biologics on achieving proof-of-mechanism for novel GAS6-AXL pathway inhibitor, AVB-S6-500, in ongoing Phase 1 trial 20 months after initiating cell line development.
Texas U.S. based Aravive Biologics, Inc. announced that the company has demonstrated clinical proof-of-mechanism for AVB-S6-500 in neutralizing GAS6, based on analysis of the single ascending dose portion of the ongoing Phase 1 study (32 subjects).
Research has shown GAS6-AXL signaling to be a key molecular pathway that is believed to promote tumor growth and metastasis, as well as tumor immune evasion and resistance to other anticancer agents. GAS6-AXL inhibition has shown potential as a strategy for the treatment of certain fibrotic diseases.
“WuXi Biologics is honored to enable Aravive to develop AVB-S6-500 with unsurpassed speed, efficiency and quality. We are very excited about the great progress of this first-in-class molecule as an innovative new therapy for people with cancers and fibrotic diseases,” said Dr. Chris Chen, Chief Executive Officer of WuXi Biologics. “We look forward to the collaboration with Aravive over the coming years on further molecules in its pipeline.”
About Aravive Biologics
Aravive Biologics is a privately held clinical stage biopharmaceutical company developing novel, highly selective therapies designed to treat serious cancers and certain fibrotic diseases. The company’s lead program is focused on the GAS6-AXL pathway. Aravive Biologics has generated strong preclinical data for its lead drug candidate AVB-S6-500 in a variety of cancer models and is currently conducting a Ph1 clinical study. The company is based in Houston, Texas, and receives support from the Cancer Prevention & Research Institute of Texas (CPRIT). For more information, please visit our website at http://www.aravive.com.
About WuXi Biologics
WuXi Biologics, a Hong Kong-listed company, is a leading global open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi Biologics, please visit www.wuxibiologics.com.
Media Contact:
WuXi Biologics
PR@wuxibiologics.com